Mesoblast Limited
MEOBF
$1.55
-$0.04-2.52%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 65.38M | 41.29M | 17.20M | 11.43M | 5.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.38M | 41.29M | 17.20M | 11.43M | 5.67M |
| Cost of Revenue | 100.26M | 75.92M | 51.58M | 44.27M | 36.95M |
| Gross Profit | -34.88M | -34.63M | -34.38M | -32.83M | -31.28M |
| SG&A Expenses | 50.66M | 45.40M | 40.13M | 35.82M | 31.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.29M | -949.50K | 395.00K | 259.50K | 124.00K |
| Total Operating Expenses | 136.16M | 107.90M | 79.64M | 68.34M | 57.04M |
| Operating Income | -70.78M | -66.61M | -62.44M | -56.91M | -51.37M |
| Income Before Tax | -93.81M | -97.81M | -101.81M | -102.52M | -103.23M |
| Income Tax Expenses | 563.00K | 446.50K | 330.00K | 226.50K | 123.00K |
| Earnings from Continuing Operations | -94.37 | -98.26 | -102.14 | -102.75 | -103.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.37M | -98.26M | -102.14M | -102.75M | -103.35M |
| EBIT | -70.78M | -66.61M | -62.44M | -56.91M | -51.37M |
| EBITDA | -64.34M | -61.26M | -58.18M | -53.80M | -49.43M |
| EPS Basic | -0.07 | -0.08 | -0.08 | -0.09 | -0.09 |
| Normalized Basic EPS | -0.04 | -0.04 | -0.05 | -0.05 | -0.05 |
| EPS Diluted | -0.07 | -0.08 | -0.08 | -0.09 | -0.09 |
| Normalized Diluted EPS | -0.04 | -0.04 | -0.05 | -0.05 | -0.05 |
| Average Basic Shares Outstanding | 5.13B | 4.98B | 4.83B | 4.66B | 4.48B |
| Average Diluted Shares Outstanding | 5.13B | 4.98B | 4.83B | 4.66B | 4.48B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |